Tools   Select Another Resource Report Type

https://www.humanbrainproject.eu/

Global, collaborative effort for neuroscience, medicine and computing to understand brain, its diseases and its computational capabilities. Goal is to obtain access to research, data sources, platforms and infrastructures offered by other organisations, and enabling organizations outside HBP to use HBP platforms to pursue their own research. Coordinating these activities is the responsibility of the European Research Programme.

Proper citation: Human Brain Project EU (RRID:SCR_002241) Copy   

•   Source: SciCrunch Registry
  

http://www.epilepsygenetics.eu/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 16,2023. Group of clinical care and epilepsy research centers who are committed to improving the lives of people with epilepsy through an understanding of the genetics of epilepsy. The consoritum was in an effort to speed discovery to epilepsy genetics by pooling the resources of several research centres., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: EPIGEN (RRID:SCR_000093) Copy   

•   Source: SciCrunch Registry
  

http://www.bioconductor.org/packages/release/data/annotation/html/RmiR.Hs.miRNA.html

Software package for various databases of microRNA Targets.

Proper citation: RmiR.Hs.miRNA (RRID:SCR_000101) Copy   

•   Source: SciCrunch Registry
  

http://knightadrc.wustl.edu/

The Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) supports researchers and our surrounding community in their pursuit of answers that will lead to improved diagnosis and care for persons with Alzheimer disease (AD). The Center is committed to the long-term goal of finding a way to effectively treat and prevent AD. The Knight ADRC facilitates advanced research on the clinical, genetic, neuropathological, neuroanatomical, biomedical, psychosocial, and neuropsychological aspects of Alzheimer disease, as well as other related brain disorders.

Proper citation: Washington University School of Medicine Knight Alzheimers Disease Research Center (RRID:SCR_000210) Copy   

•   Source: SciCrunch Registry
  

http://toc.lbg.ac.at/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 31,2025. The projected cluster includes the LBIs for Applied Cancer Research, Clinical Oncology and Photodynamic Therapy, Gynecology and Gynecologic Oncology, Stem Cell Transplantation and Surgical Oncology. The aim of the projected cluster Translational Oncology is the cooperative investigation of genetic and molecular biological characteristics of the tumor cells involved in minimal residual disease (MRD) in vitro and translation of the experimental and diagnostic results into the clinical practice involving therapeutic modalities with the newest generation of antitumoral drugs. Minimal residual disease is the designation for the occurrence of a low number of tumor cells remaining clinically undetected following curative therapy that give rise to tumor relapses. MRD is a central question in cancer therapy, since a major subpopulation of patients which underwent curative resection and therapy ultimately relapse and would have received more aggressive adjuvant therapy, provided that residual disease had been clearly proven. Otherwise low-risk patients would have not been treated aggressively in an adjuvant setting. MRD can be detected by methods in bone marrow or by extremely sensitive PCR (polymerase-chain-reaction)-based methods in peripheral blood. PCR-based methods allow for the characterization of tumor-specific gene expression in circulating tumor cells and thereby provide additional information in regard to malignity of cells and prognosis. The different participating institutions have extensive experience in patient care, organization of clinical studies and laboratory investigation. In particular, expert knowledge in stem cell transplantation and histological detection of MRD, multicentric clinical testing of new anticancer drugs, specialized treatment of various selected tumor entities such as neuroendocrine tumors, gene expression analysis of circulating tumor cells and tumor signatures, and in vitro characterization of chemosensitivity as well as tumor cell biology have been acquired at the individual LBIs in the past and are complementary to each other to be combined in a larger cluster structure. The detection of circulating tumor cells will be supported by ongoing EU (OVCAD OVarian CAncer Diagnosis) and GenAU projects aiming at identification of ovarian cancer cells in the blood. The assessment of methylated DNA sequences (suppressor genes) in peripheral blood as an indicator of MRD can be performed with the help of OncoLab Diagnostics GmbH. Cooperative action in this cluster, using a common tumor bank/clinical data collection and the combined clinical and experimental efforts are the base for the execution of the presented MRD project.

Proper citation: Ludwig Boltzmann Cluster Translationale Onkologie (RRID:SCR_000020) Copy   

•   Source: SciCrunch Registry
  

https://trialweb.dcri.duke.edu/tads/index.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 16,2023. Multi-site clinical research study examining the short- and long-term effectiveness of an antidepressant medication and psychotherapy alone and in combination for treating depression in adolescents ages 12 to 17. For teens treated in TADS, the trial is designed to provide best-practice practical care for depression.

Proper citation: TADS - Treatment for Adolescents with Depression Study (RRID:SCR_000037) Copy   

•   Source: SciCrunch Registry
  

http://www.opencolleges.edu.au/

A resource for online accredited courses in a wide variety of areas, including accounting, animal care, beauty, building and construction, business, education, design and writing. This resource is based in Australia.

Proper citation: Open Colleges (RRID:SCR_000418) Copy   

•   Source: SciCrunch Registry
  

https://nei.nih.gov/health/clinicalstudies/

An archived portal of clinical studies, both ongoing and completed, that have been conducted and supported by the National Eye Institute (NEI) since 1970. The portal covers corneal diseases, glaucoma, epidemiology, lens and cataract, retinal diseases, strabismus, amblyopia and visual processing.

Proper citation: NEI Clinical Studies (RRID:SCR_000546) Copy   

•   Source: SciCrunch Registry
  

http://www.nlmsf.org/

A volunteer, not for profit organization providing leadership in supporting research of LeioMyoSarcoma, improving treatment outcomes of those affected by this disease as well as fostering awareness in the medical community and general public. All dollars go to research and awareness. Leiomyosarcoma is a rare form of cancer, which affects about four people in every million. It spreads through the blood stream and can affect the lungs, liver, blood vessels or any other soft tissue in the body. Presently there is no cure, only remission if it can be attained, and this rare cancer can reappear anywhere and at any time. Because of its rarity, few doctors know how to treat it and it attracts little research. The National LeioMyoSarcoma Foundation hosts several Fundraising events throughout the year.

Proper citation: National LeioMyoSarcoma Foundation (RRID:SCR_004692) Copy   

•   Source: SciCrunch Registry
  

http://vision.ucsf.edu/hortonlab/index.html

Devise better ways to prevent and treat vision loss due to amblyopia and strabismus, and to advance medical science by understanding the human visual system. Various Images, Videos and Talks related to the research are available. In the Laboratory for Visual Neuroscience at the University of California, San Francisco, we are seeking to discover how visual perception occurs in the human brain. The function of the visual system is to guide our behavior by providing an efficient means for the rapid assimilation of information from the environment. As we navigate through our surroundings, a continuous stream of light images impinges on our eyes. In the back of each eye a light-sensitive tissue, the retina, converts patterns of light energy into electrical discharges known as action potentials. These signals are conveyed along the axons of retinal ganglion cells to the lateral geniculate body, a relay nucleus in the thalamus. Most of the output of the lateral geniculate body is relayed directly to the primary visual cortex (striate cortex, V1), and then to surrounding visual association areas. To understand the function of the visual pathways, our research is focused on 5 major themes: * Organization of Primary Visual Cortex * Mapping of Extrastriate Visual Cortex * Amblyopia and Visual Development * Strabismus and Visual Suppression * The Human Visual Cortex

Proper citation: UCSF Laboratory for Visual Neuroscience (RRID:SCR_004913) Copy   

•   Source: SciCrunch Registry
  

http://www.neurosci.ucsd.edu/

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 31, 2016. The Laboratory of Experimental Neuropathology is engaged in the study of neurodegenerative disease, including Alzheimer's, Parkinson's, and the dementia of HIV encephalitis. It contains a large bank of materials available to fellow investigators including images, publications, and lab safety. Fellow Investigators and Collaborators may request materials from the brain bank. Technologies employed by the laboratory include immunocytochemistry, neurochemistry, molecular genetics, transgenic models of disease, and imaging by scanning laser confocal microscopy.

Proper citation: UCSD Experimental Neuropath Laboratory (RRID:SCR_004906) Copy   

•   Source: SciCrunch Registry
  

http://www.hema-quebec.qc.ca/index.en.html

Hema-Quebec''s mission is to efficiently provide adequate quantities of safe, optimal blood components, substitutes, human tissues and cord blood to meet the needs of all Quebecers; provide and develop expertise along with specialized and innovative services and products in the fields of transfusion medicine and human tissue transplantation. Hema-Quebec is driven by the commitment, support and recognition of its employees as well as the trust of its partners to remain the standard of quality and innovation with respect to the safe procurement of blood products, human tissues and stem cells.

Proper citation: Hema-Quebec (RRID:SCR_004700) Copy   

•   Source: SciCrunch Registry
  

http://brainbank.ucla.edu/

A biomaterial supply resource which collects, stores, and distributes donated tissue to research scientists around the world. Collection occurs through the an anatomical donor program which accepts tissue donation from people with neurological/ psychiatric disorders. The Center also provides a continuous boost to biomedical research by providing high quality and quantity of pre- and post-mortem brains, spinal cords, cerebrospinal fluid (CSF), serum, blood cells and urine to use in investigations of neurological and psychiatric diseases. Scientists without a clinical site may use the Center''s readily available, high quality banked specimens.

Proper citation: Human Brain and Spinal Fluid Resource Center (RRID:SCR_004811) Copy   

•   Source: SciCrunch Registry
  

https://www.saintluc.be/en/node/2561

An essential reference center in Europe and a leader in French-speaking Belgium that treats all types of adult and childhood cancer. They fight against cancer while giving patients comprehensive and humane care. Their quest for excellence is in three main academic fields: clinical care, research and teaching.

Proper citation: Cliniques Universitaires Saint-Luc Cancer Centre (RRID:SCR_004922) Copy   

•   Source: SciCrunch Registry
  

http://www.globusmedical.com/

A privately held spinal company that is driving significant technological advancements across a complete suite of spinal products. Founded in 2003, Globus'' single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. Globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. The ultimate goal at Globus is to deliver innovation by utilizing superior engineering and technology to help improve patients'' lives. This clinical inspiration is central to every endeavor we undertake. We have developed a Spine Innovation Engine to focus our efforts on delivering industry leading solutions to surgeons and their patients. Our Spine Innovation Engine has developed a portfolio that includes a comprehensive line of technologically-advanced spine products. To date we have released over 50 major products and have over 30 more in various stages of development. Clinical Studies are the foundation for advancing innovative spine care and Globus is committed to a robust investment into prospective and retrospective clinical trials to evaluate the safety and efficacy of our products. Globus is currently conducting several FDA-approved Investigational Device Exemption (IDE) clinical studies.

Proper citation: Globus Medical, Inc. (RRID:SCR_004836) Copy   

•   Source: SciCrunch Registry
  

http://www.tbregistry.org/

A non-profit organization that promotes research on hearing and balance disorders. The Registry database allows researchers to perform simple searches to locate specimens of interest. The results show the laboratories where specimens that match the query are located. Investigators should contact the individual laboratories for studying the specimens or for access to the sections. The Registry also serves the public and the scientific community through the dissemination of public information on temporal bone donation and research, enrollment of temporal bone donors, publication of The Registry, a newsletter for researchers, conservation of existing human temporal bone collections, and professional educational activities for physicians and scientists.

Proper citation: National Temporal Bone Pathology Resource Registry (RRID:SCR_004705) Copy   

•   Source: SciCrunch Registry
  

https://www.bannerhealth.com/research/locations/sun-health-institute/programs/body-donation

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. An autopsy-based, research-devoted brain bank, biobank and biospecimen bank that derives its human donors from the Arizona Study of Aging and Neurodegenerative Disease (AZSAND), a longitudinal clinicopathological study of the health and diseases of elderly volunteers living in Maricopa county and metropolitan Phoenix, Arizona. Their function is studied during life and their organs and tissue after death. To date, they have concentrated their studies on Alzheimer's disease, Parkinson's disease, heart disease and cancer. They share the banked tissue, biomaterials and biospecimens with qualified researchers worldwide. Registrants with suitable scientific credentials will be allowed access to a database of available tissue linked to relevant clinical information, and will allow tissue requests to be initiated., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Brain and Body Donation Program (RRID:SCR_004822) Copy   

•   Source: SciCrunch Registry
  

http://www.chdifoundation.org/

A private, not-for-profit research organization that serves as an international collaborative enabler in order to discover drugs that slow the progression of Huntington's disease (HD). The activities of CHDI extend from exploratory biology to the identification and validation of therapeutic targets, and from drug discovery and development to clinical studies and trials. CHDI works with biotech and pharmaceutical companies and funds and works with academic HD researchers at universities.

Proper citation: CHDI Foundation (RRID:SCR_004622) Copy   

•   Source: SciCrunch Registry
  

http://spot.colorado.edu/~dubin/talks/brodmann/brodmann.html

Reference atlas of Brodmann Areas in the Human Brain with an Emphasis on Vision and Language. Other Pages include: Flat Brodmann Maps, Brodmann Area Names (with locational Descriptions), Flat Visual Area Maps, Language Areas, PopUp Gyri Maps

Proper citation: Brodmann Areas in the Human Brain with an Emphasis on Vision and Language (RRID:SCR_004857) Copy   

•   Source: SciCrunch Registry
  

http://www.tbidx.net

Network evaluating consensus-based common data elements (CDE) for traumatic brain injury (TBI) and psychological health (TBI-CDE, www.commondataelements.ninds.nih.gov/TBI.aspx) while extensively phenotyping a cohort of TBI patients across the injury spectrum from concussion to coma. Institutions that participate in the TBI Network will be able to track the outcomes of patients through a 3, 6 and 12-month followup program and compare outcomes with other participating institutions. For the three acute care centers, patients were enrolled that presented to the emergency department within 24 hours of head injury and required computed tomography (CT). For the rehabilitation center, referrals from acute hospitals were enrolled. Patients were consented to participate in components: clinical profile; blood draws for measurement of proteomic and genomic markers; 3T MRI within 2 weeks; three-month Glasgow Outcome Scale-Extended (GOS-E); and six-month TBI-CDE Core outcome assessments. A web-enabled database, imaging repository, and biospecimen bank was developed using the TBI-CDE recommendations. A total of 605 patients were enrolled. Of these subjects, 88% had a GCS 13-15, 5% had a GCS 9-12, and 7% had a GCS of 8 or less. Three-month GOS-E''s were obtained for 78% of the patients. Comprehensive 6-month outcome measures, including PTSD assessment, are ongoing until September 2011. Blood specimens were collected from 450 patients. Initial CTs for 605 patients and 235 patients with 3T MRI studies were transferred to an imaging repository. The TRACK TBI Network will provide qualified institutions access to a web-based version of key forms in tracking TBI outcomes for Quality Improvement and institutional benchmarking.

Proper citation: TRACK TBI Network (RRID:SCR_004723) Copy   

•   Source: SciCrunch Registry